82 results about "Antipsychotics drugs" patented technology

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.

Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.

The invention relates to a sustained-release microsphere of antipsychotic drug risperidone and the preparation method thereof.

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved since the first day up to at least 14 days or more even up to at least four weeks.

New methods of treating schizophrenia and schizoaffective disorder by administration of pharmaceutical compositions comprising an antipsychotic compound and a VMAT2 inhibitor to a subject in need thereof are provided.

The present invention relates to pharmaceutical compositions comprising a compound of Formula (I) that are useful for the intramuscular delivery of antipsychotic drugs using rapid injection rates.

The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia.

The invention belongs to the field of biotechnology, and relates to an lncRNA marker and a kit for depression diagnosis. The lncRNA marker for depression diagnosis provided by the invention consists of TCONS_l2_00001212, NONHSAT102891, TCONS_00019174, ENST00000566208, NONHSAG045500, ENST00000517573, NONHSAT034045 and NONHSAT142707, and the primer sequences of the eight lncRNAs are as shown in SEQ ID NO.1-SEQ ID NO.16; the invention also provides probes for the eight lncRNAs are as shown in SEQ ID NO.17-SEQ ID NO.24. The invention disclosed by the invention has the beneficial effects that a biomarker for depression and a biomarker for assessing the curative effect of an antipsychotic drug are provided for the first time. Upon clinical verification, the lncRNA is relatively high in specificity and sensitivity and is relatively high in diagnosis reference value; and the lncRNA, as a specific depression biomarker can make revolutionary change on the diagnosis and the treatment of the depression.

The invention relates to a method for detecting the liquid quality of an antipsychotic drug in serum or plasma and pretreatment of a specific purification material of the antipsychotic drug. The method comprises the following steps: a serum or plasma sample is subjected to protein precipitation by a certain proportion of organic reagents; a supernatant obtained through centrifugal precipitation ispretreated with a specific purification material to obtain a purified sample solution, the purified sample solution is subjected to liquid chromatography-tandem mass spectrometry detection and analysis, and eight antipsychotic drugs including olanzapine, clozapine, quetiapine, aripiprazole, flupiperidinol, risperidone, pariperidone and ziprasidone in serum or plasma are detected at the same time.The pretreatment of the specific purification material is a mixed solid-phase extraction column taking silica gel as a matrix, and the blood is purified by the specific purification material, so thatthe interference of the matrix in the blood can be removed, the matrix effect of eight antipsychotic drugs can be improved, and the recovery rate of the antipsychotic drugs can be better ensured.

The present invention identifies genotypes associated with resistance to extrapyramidal symptoms induced by antipsychotic drugs. The present invention further identifies genotypes associated with predisposition to the onset or aggravation of extrapyramidal symptoms induced by antipsychotic drugs and use thereof for assessment of patient populations. Specifically, the present invention relates to particular polymorphisms in the RGS2 gene that are associated with resistance or susceptibility to drug-induced extrapyramidal symptoms.

The invention provides a method for simultaneously detecting the concentrations of various antipsychotic drugs in serum. According to the method, 16 kinds of antipsychotic drugs can be detected at a time; target drugs and metabolites are monitored at the same time; the method is high in sensitivity, high in specificity, good in accuracy and simple in pretreatment process; separation and detectionof the antipsychotic drugs in serum are completed within 5.0 minutes, and the accuracy and precision of the method basically meet requirements; and the method can be used for quantitative analysis ofantipsychotic drugs in serum clinically, and a simple and rapid detection method is provided for concentration monitoring of antipsychotic drugs clinically.

This invention relates to pharmaceutical compositions of riluzole in combination with levodopa and methods of treating Parkinson's disease and alleviating levodopa-induced dyskinesia and tardive dyskinesia therewith. Pharmaceutical compositions of riluzole in combination with an antipsychotic drug are also provided for use in the treatment of behavioral and psychiatric disorders treatable with an antipsychotic drug.

The invention is related to a novel primate specific brain isoform of the potassium channel KCNH2 and genetic association with risk for schizophrenia and response to therapy.

Belonging to the medical technology field, the invention in particular relates to a maleic acid asenapine compound and a preparation method thereof. The invention also relates to application of compositions containing the maleic acid asenapine compound in preparation of drugs treating antipsychotic drugs.

A liquid chromatography method for detecting the content of an olanzapine drug in blood comprises the following steps: calibrating standard solutions by using a liquid chromatograph and an ultravioletdetector, performing fitting to obtain a standard curve equation y = a*x + b, taking a blood sample to be detected, processing the blood to be detected, detecting the blood to be detected by using the liquid chromatograph and the ultraviolet detector to obtain the y value of the blood to be detected, substituting the y value of the blood to be detected into the standard curve equation, and calculating the concentration of the olanzapine drug in the blood to be detected. The method combines an external standard technology with high performance liquid chromatography, and is suitable for high-throughput sample detection; and a small particle size column and a low flow rate are adopted to reduce the consumption of an organic solvent, so the experimental cost is reduced, environmental protection is achieved, monitoring the plasma concentration of olanzapine in a patient during clinical treatment is facilitated, and an experimental basis is provided for the personalized administration of the antipsychotic drug olanzapine and the reduction of toxic and side effects.

The invention provides a preparation method of a novel antipsychotic drug iloperidone, which comprises the following steps that: 6-fluoro-3-(4-piperidinyl)-1,2-benzo isoxazole hydrochloride is reacted with 1-[4-(3- chlorophenoxy)-3-methoxyphenyl]ethanone in an aqueous solution of a non-ionic surfactant by using an inorganic base as an acid binding agent and potassium iodide as a catalyst to obtain the iloperidone. The process has the advantages of high yield, high purity, good product appearance, simpleness and convenience in operation, and low cost, has no adverse impact on the environment, and is very suitable for industrial mass production.

The invention discloses a kit for simultaneously detecting multiple antipsychotic drugs in serum. An LC-MS / MS method is adopted; 16 common antipsychotic drugs can be detected at one time; the kit is simple in pretreatment process, low in cost, high in sensitivity and high in specificity; separation and detection of the antipsychotic drug are completed within 5 min, accuracy and precision basicallymeet the requirements, the kit can be used for quantitative analysis of the clinical antipsychotic drug, and a reliable detection method is provided for monitoring the treatment concentration of theclinical antipsychotic drug.

The present invention provides combinations of an antipsychotic drug and a tetracycline, particularly minocycline, for the treatment of psychotic disorders, particularly schizophrenia. The invention also provides formulations wherein the release of one or both of the antipsychotic drug and the tetracycline is modified. The invention also provides methods using the combined therapy for treatment of psychotic disorders, particularly schizophrenia, comprising an antipsychotic drug and a tetracycline.

Disclosed are benzoisothiazole compounds and a use in the preparation of anti-schizophrenia drugs. The benzoisothiazole compounds of the present invention not only have strong affinity for dopamine D3 receptor, 5-HT1A receptor and 5-HT2A receptor, but also can observably improve the symptoms of schizophrenia relevant to apomorphine model and MK-801 model mice, with oral absorption being good, safety being high and side-effect being less, and having developmental value as new anti-neurotic disease drugs. The present invention is the compounds having a structure of general formula (I), or geometric isomers, free alkalies, salts, hydrates or solvates thereof.

The present invention relates to a novel salt of (3aR,4S,7R,7aS)-2-[((1R,2R)-2-{[4-(1,2-benzisothiazol-3-yl)-piperazin-1-yl]methyl}cyclohexyl)methyl]hexahydro-1H-4,7-methanisoindol-1,3-dione and hydrates thereof, to methods for preparing the novel salt and its hydrates. In one aspect, the present invention provides a compound which is lurasidone dihydrochloride. In another aspect, the present invention provides a process for preparation of lurasidone dihydrochloride comprising: (i) mixing lurasidone free base in an organic solvent system; (ii) subjecting step (i) mixture to acid proton source; and (iii) isolating compound of lurasidone dihydrochloride.

The present invention is directed to a composition that can be used to deliver an antipsychotic drug such as risperidone, paliperidone or a combination thereof, as an injectable in-situ forming biodegradable implant for extended release providing therapeutic plasma levels from the first day. The composition is in the form of drug suspension on a biodegradable and biocompatible copolymer or copolymers solution using water miscible solvents that is administered in liquid form. Once the composition contacts the body fluids, the polymer matrix hardens retaining the drug, forming a solid or semisolid implant that releases the drug in a continuous manner. Therapeutic plasma levels of the drug can be achieved from the first day up to at least 14 days or more even up to at least four weeks.

Disclosed herein are methods of treating disorders of the retina (e.g., macular degeneration, retinitis pigmentosa, etc.) comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound (for example, an antipsychotic drug) that blocks or diminishes agonist-mediated responses upon binding to either dopamine D2-like receptors or serotonin 5-HT2 receptors.

Several embodiments disclosed herein relate to methods for calculating a dosing regimen that is tailored specifically to the genetic and metabolic profile of a particular patient. In some embodiments, the dosing regimen is related to administration of the antipsychotic drug clozapine, and the tailoring of the regimen reduces risk of adverse side effects.